UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

£28m investment in AI diagnostics for the UK health service is welcome, but only one piece of the puzzle in reducing wait times.

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

TEST
TEST

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

AI-powered X-ray tools for radiologists in lung cancer will be rolled out to all NHS trusts in England by 2029,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C13

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C12

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

More from Regulatory Landscape

Kashiv Finishes Patient Recruitment In Late Stage Xolair Biosimilar Trial

 
• By 

Following on from its recently announced US licensing deal with Amneal over its Xolair biosimilar, Kashiv has finished patient recruitment for a trial for the omalizumab candidate, paving the way for submissions.

GB-Policy&Regulation (Premium-1): Lead Exposure Is Still a Problem for Kids, and the Pandemic Has Made It Worse

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.